Patoloxía Molecular das Doenzas Raras
PatMol-DR
Harvard Medical School
Boston, Estados UnidosPublicacións en colaboración con investigadores/as de Harvard Medical School (7)
2024
-
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial
The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 10, pp. 725-734
2022
-
Management of early treated adolescents and young adults with phenylketonuria: Development of international consensus recommendations using a modified Delphi approach
Molecular Genetics and Metabolism, Vol. 137, Núm. 1-2, pp. 114-126
-
The Role of Fatty Acid-Binding Protein 4 in the Characterization of Atrial Fibrillation and the Prediction of Outcomes after Catheter Ablation
International Journal of Molecular Sciences, Vol. 23, Núm. 19
2020
-
Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name
Metabolism: Clinical and Experimental, Vol. 113
-
α-Synuclein strains target distinct brain regions and cell types
Nature Neuroscience, Vol. 23, Núm. 1, pp. 21-31
2019
-
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628
-
Management and 1-year outcomes of patients with newly diagnosed atrial fibrillation and chronic kidney disease: Results from the prospective garfield-af registry
Journal of the American Heart Association, Vol. 8, Núm. 3